Related references
Note: Only part of the references are listed.Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab
Sabine Tischer-Zimmermann et al.
FRONTIERS IN IMMUNOLOGY (2023)
Epigenetic control of the Epstein-Barr lifecycle
Rui Guo et al.
CURRENT OPINION IN VIROLOGY (2022)
Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization
Ayako Kume et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2022)
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Qian Li et al.
FRONTIERS IN IMMUNOLOGY (2022)
Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
Nicholas J. Bevins et al.
Journal of Immunotherapy and Precision Oncology (2022)
Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas
Helen E. Heslop et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Cytotoxic CD4+T-cells specific for EBV capsid antigen BORF1 are maintained in long-term latently infected healthy donors
Alexander Dowell et al.
PLOS PATHOGENS (2021)
Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation
Susan Prockop et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment
Katie Hudson et al.
FRONTIERS IN IMMUNOLOGY (2020)
PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
Yongshuai Jiang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2019)
Myeloid loss of Beclin 1 promotes PD-L1hi precursor B cell lymphoma development
Peng Tan et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Epstein–Barr Virus and Cancer
Paul J. Farrell
Annual Review of Pathology-Mechanisms of Disease (2018)
CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer
Shu Su et al.
ONCOIMMUNOLOGY (2017)
Phase I Clinical Trial of 4-1BB-based Adoptive T-Cell Therapy for Epstein-Barr Virus (EBV)-positive Tumors
Hyeon-Seok Eom et al.
JOURNAL OF IMMUNOTHERAPY (2016)
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
Genevieve M. Weir et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Epstein-Barr virus: more than 50 years old and still providing surprises
Lawrence S. Young et al.
NATURE REVIEWS CANCER (2016)
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Stephen M. Ansell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Enhanced antitumor effect of combining chemotherapy with Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes in mice with EBV-related non-Hodgkin's lymphoma
Rui Deng et al.
MOLECULAR AND CLINICAL ONCOLOGY (2015)
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
Taku Okazaki et al.
NATURE IMMUNOLOGY (2013)
Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
Ekaterina Doubrovina et al.
BLOOD (2012)
siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
K. Iwamura et al.
GENE THERAPY (2012)
Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype
Santiago Montes-Moreno et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs
S Gottschalk et al.
BLOOD (2001)
Share Paper
